Objective:
The genetic hallmark of CML is known as the appearance of t(9;22)(q34.1;q11.2) (BCR-ABL1) which is present in more than 95% of cases. Here, we demonstrated practical laboratory tools for monitoring of BCR-ABL1 transcripts in chronic myeloid leukemia patients undergoing TK inhibitor therapy.
Methods:
Real time quantitative PCR and direct sequencing were performed for monitoring of BCR-ABL1 transcripts in 245 treated CML.
Results:
At month 3 after first time point of monitoring, we found that 89% (218/245), 2% (5/245), and 9% (22/245) of patients are determined as optimal, warning, and failure response, respectively. The responses to TKI were slightly decreased at months 6 as following 73% optimal (180/245), 18% warning (43/245), and 9% failure response (22/245). Additionally, responses to TKI were gradually decreased at month 12 after first time point of monitoring as following 65% optimal (160/245), 13% warning (31/245), and 22% failure (54/245). We could detect 20% (49/245) of patients positive for
BCR-ABL1
TKD mutations. Interestingly, one third (17 of 49) of TKD mutated cases were positive for compound/polyclonal mutation patterns. While major molecular response were observed in the majority of patients without TKD mutation, resistant to TKI were detected in patients with
T315I
mutation (n = 9; % mean IS = 8.1510, % median IS = 9.7000), compound/polyclonal mutations with T315I (n = 9; % mean IS = 13.0779, % median IS = 5.404), and other TKD mutations (n = 14; % mean IS = 8.1416, % median IS = 1.060), respectively.
Conlusion:
These practical laboratory techniques provided a more comprehensive understanding of CML progression during drug therapy and could be of benefit in earlier prognosis.
Background:
Epithelial ovarian cancer (EOC) is often challenging to diagnose, even though histological
examination. microRNA (miRNA or miRNA) is bound to the target messenger RNA (mRNA) and causing the mRNA
molecules are silenced. The identification of miRNA expression-based EOC subtypes is considered a critical means of
prognostication. So far, the studies on EOC subtypes have not been well characterized.
Objective:
This study aimed to confirm the existence of miRNAs in EOC and to assess their potential as clinical
biomarkers for EOC.
Methods:
We sampled 25 ovarian tumor tissues from patients with human ovarian tumors (17 malignant; 12 serous EOC,
five non-serous EOC, and eight benign ovarian tumors). miRNA microarray detection was performed to identify EOC
miRNAs. Real-time PCR was adapted for the validation of differentially expressed miRNAs detected by microarray
analysis was related to hybridization intensity.
Results:
The results confirmed that miRNAs exist in EOC, relative expression of EOC miRNAs demonstrated that
upregulation of miR-483-5p, and downregulation of miR-127-3p, and miR-532-5p were significantly expressed in the
malignant group than in the benign group at p ' 0.05. Besides, miR-483-5p could also distinguish EOC subtypes between
serous EOC and non-serous EOC, with a p ' 0.05.
Conclusion:
A comprehensive miRNA expression profiling can help to refine subtype classification in EOC, opening new
opportunities for identifying clinically applicable markers for improved stratification and diagnostics of ovarian tumors.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.